These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28488185)

  • 41. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of relapsed and refractory Hodgkin Lymphoma.
    von Tresckow B; Moskowitz CH
    Semin Hematol; 2016 Jul; 53(3):180-5. PubMed ID: 27496309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
    Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
    Sasse S; Alram M; Müller H; Smardová L; Metzner B; Doehner H; Fischer T; Niederwieser DW; Schmitz N; Schäfer-Eckart K; Raemaekers JM; Schmalz O; Tresckow BV; Engert A; Borchmann P
    Leuk Lymphoma; 2016 May; 57(5):1067-73. PubMed ID: 26693800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New therapy outlooks in Hodgkin lymphoma].
    Rossi C; Casasnovas RO
    Bull Cancer; 2017 Feb; 104(2):182-194. PubMed ID: 28088309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What is the best salvage therapy for Hodgkin lymphoma?
    Luttwak E; Moskowitz AJ
    Curr Opin Oncol; 2024 Sep; 36(5):346-352. PubMed ID: 39007229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapsed Hodgkin lymphoma: management strategies.
    Montanari F; Diefenbach C
    Curr Hematol Malig Rep; 2014 Sep; 9(3):284-93. PubMed ID: 24942298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salvage therapy in Hodgkin's lymphoma.
    Mendler JH; Friedberg JW
    Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
    Moskowitz AJ; Perales MA; Kewalramani T; Yahalom J; Castro-Malaspina H; Zhang Z; Vanak J; Zelenetz AD; Moskowitz CH
    Br J Haematol; 2009 Jul; 146(2):158-63. PubMed ID: 19438504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.
    Isidori A; Piccaluga PP; Loscocco F; Guiducci B; Barulli S; Ricciardi T; Picardi P; Visani G
    Expert Rev Hematol; 2013 Aug; 6(4):451-64. PubMed ID: 23991931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability.
    Xavier FD; Farias DLC; Neto AEH; Ribeiro GN; Araujo MAS; Carneiro TX; Baiocchi OCCG
    Oncotarget; 2023 Dec; 14():977-994. PubMed ID: 38085126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
    Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
    Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
    Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
    J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.